EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH

Novia Nurul Faizah iD, Gusty Rizky Teguh Ryanto iD, Sagita Mega Sekar Kencana iD, Yoko Suzuki iD, Tetsuya Hara iD, Hiromasa Otake iD, Noriaki Emoto iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2026

DOI: 10.1161/atvbaha.125.323681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Novia Nurul Faizah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Chuo, Japan (N.N.F., S.M.S.K., T.H…. Hauptthemen laut MEDLINE: Endothelin-1, Vascular Remodeling, Activins, Pulmonary Artery. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pulmonary arterial hypertension remains a life-threatening disease despite advances in vasodilator therapy. Vascular remodeling, partly driven by pulmonary artery endothelial cell dysfunction, is accompanied by vasoactive mediators imbalance such as ET-1 (endothelin-1). Although endothelin receptor antagonists alleviate vasoconstriction, they incompletely address the remodeling process. We previously reported how endothelial-derived activin A promotes vascular remodeling, leading to the clinical development of the activin signaling inhibitor sotatercept, which improves outcomes when added to endothelin receptor antagonists. As both activin A and ET-1 originate from endothelial cells and promote remodeling, we investigated whether activin A regulates ET-1 production and activity in pulmonary arterial hypertension. METHODS: In vitro, we used pulmonary artery endothelial cell models of activin A overabundance alone or cocultured with pulmonary artery smooth muscle cells. Cells were treated with either the activin A inhibitor FST (follistatin), the endothelin receptor antagonist bosentan, the FST/bosentan combination, or vehicle for analysis. In vivo, we exposed wild-type or endothelial-specific INHBA (inhibin β-A)-overexpressing mice (VEcadherin-INHBA-Transgenic/VEcad-INHBA-Tg) to chronic hypoxia pulmonary hypertension model, with the addition of FST, bosentan, FST and bosentan, or vehicle treatments after the first week of hypoxia exposure. RESULTS: Activin A upregulated ET-1 expression via canonical SMAD2/3 (small mother against decapentaplegic family member 2/3) signaling in pulmonary artery endothelial cells. This induction, as well as ET-1–driven downstream effects—including reduced eNOS (endothelial NO synthase), pulmonary artery smooth muscle cell phenotypic switching, oxidative stress, and endothelial-to-mesenchymal transition—was reversed by FST alone or in combination with bosentan. In vivo, FST-based therapy achieved greater hemodynamic, right ventricular remodeling, and vascular structural normalization in wild-type and VEcad-INHBA-Tg mice than bosentan alone, accompanied by stronger ET-1 suppression. CONCLUSIONS: We identified ET-1 as a downstream effector of activin A in pulmonary arterial hypertension development, supporting activin A blockade as a strategy to inhibit ET-1–mediated vasoconstriction and remodeling. This mechanistic link provides a rationale for the rapid clinical benefits observed with sotatercept and suggests its potential role earlier in the pulmonary arterial hypertension treatment paradigm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelin-1Vascular RemodelingActivinsPulmonary ArteryEndothelial CellsPulmonary Arterial HypertensionHypertension, PulmonaryAnimalsDisease Models, AnimalCells, CulturedSignal TransductionHumansMyocytes, Smooth MuscleMice, TransgenicCoculture TechniquesBosentanMice, Inbred C57BLMaleMuscle, Smooth, VascularMice

Stichwörter der Autor:innen

activin Aendothelin-1follistatinpulmonary arterial hypertensionvascular remodeling

Substanzen

Endothelin-1Activinsactivin ABosentan

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Chuo, Japan (N.N.F., S.M.S.K., T.H., H.O., N.E.).
  • Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Higashinada, Japan (N.N.F., G.R.T.R., S.M.S.K., Y.S., T.H., N.E.).

ORCID-Profile: Novia Nurul Faizah, Gusty Rizky Teguh Ryanto, Sagita Mega Sekar Kencana, Yoko Suzuki, Tetsuya Hara, Hiromasa Otake, Noriaki Emoto

Zitieren

APA

Faizah, N. N., Ryanto, G. R. T., Kencana, S. M. S., Suzuki, Y., Hara, T., Otake, H., & Emoto, N. (2026). Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.125.323681

Vancouver

Faizah NN, Ryanto GRT, Kencana SMS, Suzuki Y, Hara T, Otake H, et al. Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.125.323681

BibTeX
@article{Faizah2026,
  author = {Faizah, Novia Nurul and Ryanto, Gusty Rizky Teguh and Kencana, Sagita Mega Sekar and Suzuki, Yoko and Hara, Tetsuya and Otake, Hiromasa and Emoto, Noriaki},
  title = {Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2026},
  doi = {10.1161/atvbaha.125.323681}
}
Kostenlos starten →